Cargando…
Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase
Inorganic anions inhibit the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) generally by coordinating to the active site metal ion. Cyanate was reported as a non-coordinating CA inhibitor but those erroneous results were subsequently corrected by another group. We review the anion CA inhibitors (...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901698/ https://www.ncbi.nlm.nih.gov/pubmed/33615947 http://dx.doi.org/10.1080/14756366.2021.1882453 |
_version_ | 1783654411967397888 |
---|---|
author | Nocentini, Alessio Angeli, Andrea Carta, Fabrizio Winum, Jean-Yves Zalubovskis, Raivis Carradori, Simone Capasso, Clemente Donald, William A. Supuran, Claudiu T. |
author_facet | Nocentini, Alessio Angeli, Andrea Carta, Fabrizio Winum, Jean-Yves Zalubovskis, Raivis Carradori, Simone Capasso, Clemente Donald, William A. Supuran, Claudiu T. |
author_sort | Nocentini, Alessio |
collection | PubMed |
description | Inorganic anions inhibit the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) generally by coordinating to the active site metal ion. Cyanate was reported as a non-coordinating CA inhibitor but those erroneous results were subsequently corrected by another group. We review the anion CA inhibitors (CAIs) in the more general context of drug design studies and the discovery of a large number of inhibitor classes and inhibition mechanisms, including zinc binders (sulphonamides and isosteres, dithiocabamates and isosteres, thiols, selenols, benzoxaboroles, ninhydrins, etc.); inhibitors anchoring to the zinc-coordinated water molecule (phenols, polyamines, sulfocoumarins, thioxocoumarins, catechols); CAIs occluding the entrance to the active site (coumarins and derivatives, lacosamide), as well as compounds that bind outside the active site. All these new chemotypes integrated with a general procedure for obtaining isoform-selective compounds (the tail approach) has resulted, through the guidance of rigorous X-ray crystallography experiments, in the development of highly selective CAIs for all human CA isoforms with many pharmacological applications. |
format | Online Article Text |
id | pubmed-7901698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-79016982021-03-04 Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase Nocentini, Alessio Angeli, Andrea Carta, Fabrizio Winum, Jean-Yves Zalubovskis, Raivis Carradori, Simone Capasso, Clemente Donald, William A. Supuran, Claudiu T. J Enzyme Inhib Med Chem Review Article Inorganic anions inhibit the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) generally by coordinating to the active site metal ion. Cyanate was reported as a non-coordinating CA inhibitor but those erroneous results were subsequently corrected by another group. We review the anion CA inhibitors (CAIs) in the more general context of drug design studies and the discovery of a large number of inhibitor classes and inhibition mechanisms, including zinc binders (sulphonamides and isosteres, dithiocabamates and isosteres, thiols, selenols, benzoxaboroles, ninhydrins, etc.); inhibitors anchoring to the zinc-coordinated water molecule (phenols, polyamines, sulfocoumarins, thioxocoumarins, catechols); CAIs occluding the entrance to the active site (coumarins and derivatives, lacosamide), as well as compounds that bind outside the active site. All these new chemotypes integrated with a general procedure for obtaining isoform-selective compounds (the tail approach) has resulted, through the guidance of rigorous X-ray crystallography experiments, in the development of highly selective CAIs for all human CA isoforms with many pharmacological applications. Taylor & Francis 2021-02-21 /pmc/articles/PMC7901698/ /pubmed/33615947 http://dx.doi.org/10.1080/14756366.2021.1882453 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Nocentini, Alessio Angeli, Andrea Carta, Fabrizio Winum, Jean-Yves Zalubovskis, Raivis Carradori, Simone Capasso, Clemente Donald, William A. Supuran, Claudiu T. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase |
title | Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase |
title_full | Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase |
title_fullStr | Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase |
title_full_unstemmed | Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase |
title_short | Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase |
title_sort | reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901698/ https://www.ncbi.nlm.nih.gov/pubmed/33615947 http://dx.doi.org/10.1080/14756366.2021.1882453 |
work_keys_str_mv | AT nocentinialessio reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase AT angeliandrea reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase AT cartafabrizio reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase AT winumjeanyves reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase AT zalubovskisraivis reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase AT carradorisimone reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase AT capassoclemente reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase AT donaldwilliama reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase AT supuranclaudiut reconsideringanioninhibitorsinthegeneralcontextofdrugdesignstudiesofmodulatorsofactivityoftheclassicalenzymecarbonicanhydrase |